A vaccine against HTLV-1 HBZ makes sense.
In this issue of Blood, Sugata et al report that vaccination against human T-cell leukemia virus type 1 (HTLV-1) basic leucine zipper (bZIP) factor (HBZ) could be used for immunotherapy in adult T-cell leukemia-lymphoma (ATL) patients.